William Pevsner, DO
Family Medicine · San Dimas, CANPI 1679758171
Payments from drug & device makers
Across 370 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amarin Pharma, Inc.$908
- AbbVie$691
- Boehringer Ingelheim$674
- Novo Nordisk$547
- Takeda Pharmaceuticals U.S.A., Inc.$520
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,593100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $1,017 |
| Amarin Pharma, Inc. | 62 | $908 |
| AbbVie(2 entities) | 55 | $691 |
| Boehringer Ingelheim | 29 | $674 |
| Novo Nordisk | 24 | $547 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $520 |
| Esperion Therapeutics, Inc. | 16 | $299 |
| Pfizer | 9 | $187 |
| Biohaven Pharmaceuticals, Inc. | 12 | $179 |
| Bayer | 9 | $175 |
| Otsuka America Pharmaceutical, Inc. | 8 | $158 |
| Amgen(2 entities) | 8 | $149 |
| Johnson & Johnson | 5 | $126 |
| Lilly USA, LLC | 6 | $121 |
| Sanofi-aventis U.S. LLC | 7 | $117 |
| Merck | 6 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $74 |
| Arbor Pharmaceuticals, Inc. | 3 | $69 |
| Novartis | 3 | $66 |
| GSK | 3 | $64 |
| Lundbeck LLC | 2 | $46 |
| Exact Sciences | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Cequr Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,611 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $138,579 |
| FarxigaDapagliflozin Propanediol | 98 | $119,524 |
| JardianceEmpagliflozin | 74 | $98,184 |
| EliquisApixaban | 94 | $63,134 |
| TrulicityDulaglutide | 17 | $16,666 |
| EntrestoSacubitril/Valsartan | 22 | $15,940 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $15,889 |
| MounjaroTirzepatide | 11 | $11,662 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $10,029 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $9,730 |
| LinzessLinaclotide | 16 | $9,032 |
| XareltoRivaroxaban | 11 | $8,497 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,414 |
| VascepaIcosapent Ethyl | 14 | $8,410 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,017 | $138,901135 claims |
| Novo NordiskOzempic | $547 | $138,579137 claims |
| Boehringer IngelheimJardiance | $674 | $98,18474 claims |
| PfizerEliquis | $187 | $63,13494 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $121 | $28,32828 claims |
| NovartisEntresto | $66 | $15,94022 claims |
| AbbVieLinzess, Synthroid | $691 | $10,85948 claims |
| MerckJanumet | $107 | $10,02911 claims |
| GSKBreo Ellipta | $64 | $9,73025 claims |
| Johnson & JohnsonXarelto | $126 | $8,49711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $520 | $5,89911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in San Dimas
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.